Policy & Regulation
Stemcell Technologies to Commercialise Propagenix' EpiX Cell Culture Medium
22 September 2017 - - Vancouver, British Columbia-based cell biology specialist Stemcell Technologies has signed an exclusive license agreement with Rockville, Maryland-based regenerative medicine company Propagenix to commercialise its patented EpiX technology, a novel cell culture medium that enables expansion of tissue-resident epithelial stem cells without any genetic manipulation, the company said.
Whereas current cell culture systems typically yield fewer than 20 population doublings before the cells senesce, epithelial stem cells derived from many tissue types can be propagated more than a trillion-fold in Epix.
The Epix expanded cells are genetically stable, are not tumorigenic, and can be readily differentiated into tissue-specific phenotypes even after extensive expansion.
Stemcell is committed to providing high-quality cell culture media, cell isolation products, accessory reagents and services for life science research.
The company offers over 2500 products designed to support the basic to translational research continuum.
Propagenix is applying its proprietary technologies to internal and partnered cell therapy programs. The company's technology platform has proven ability for propagating tissue-resident epithelial stem cells of diverse tissue origins with unparalleled production efficiency, reliable safety, and predictable in vivo functionality.
In addition to cell therapeutics, Propagenix's technology addresses key bottlenecks in using primary cell models for drug discovery and toxicology, as well as creating new possibilities for use of patient-specific samples for precision medicine applications in oncology and respiratory disease.
Login
Username:

Password: